On a volatile day when the Dow Jones Industrial Average (INDEX: ^DJI ) fell nearly 250 points as the feckless Congressional supercommittee left no doubt that partisan intransigence would supersede any debt deal, significantly large moves happened in the health-care sector. For instance, a week after after announcing the elimination of its stem-cell program, Geron
Let's focus on three biotechs that made moves because of breaking news.
Speaking of which, Pharmasset
Gilead is getting PSI-7977, an oral treatment that doesn't require interferon injections and their nasty side effects. Oral-drug candidates such as Pharmasset's PSI-7977, Inhibitex's INX-189, and Achillion's ACH-1625 are the potential future backbone of drug cocktails used for attacking hepatitis C. Gilead has a host of hep-C drugs in its pipeline, and its work with HIV shows that it's adept at creating effective drug combinations. The multibillion-dollar race for hepatitis C treatment supremacy is well under way.
The best way to track the latest developments surrounding the companies mentioned above is to add them to our free My Watchlist feature:
- Add Pharmasset to My Watchlist.
- Add Gilead Sciences to My Watchlist.
- Add Vertex to My Watchlist.
- Add Spectrum Pharmaceuticals to My Watchlist.
- Add Regeneron to My Watchlist.
- Add Geron to My Watchlist.
- Add Alexa Pharmaceuticals to My Watchlist.
If you think the billions at stake in hepatitis C treatments are a big deal, wait until you read The Motley Fool's special free report, " The Next Trillion Dollar Revolution ." Don't miss out on your chance to profit from this massive market opportunity.
David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.